

Summary Table of Actions





Strategy 1: Awareness

Action Plan	Action party	Timeline
1.1 Awareness campaign for the general population		
1.1.1 Revamp the website of Viral Hepatitis Control Office to provide up-to-date information and to improve user experience	DH	Completed
1.1.2 Review and update the information of the website of Viral Hepatitis Control Office	DH	2023Q2
1.1.3 Define yearly themes of awareness campaign across the territory	SCVH	Completed for 2020-22
1.1.4 Establish the yearly theme for 2023 – 2024	DH	2022Q4
1.1.5 Launch enhanced awareness campaign, involving Kwai Tsing District Health Centre	DH & DHC	2020Q3
1.2 Professional training for healthcare workers		
1.2.1 Conduct professional training programmes with the KAP assessment by phases, starting for obstetricians and midwives and extending to other groups of healthcare workers under the similar framework	HA, DH & constituent Colleges of Hong Kong Academy of Medicine	Yearly
1.3 Education targeting at-risk populations, patients and their service providers		
1.3.1 Develop focused education materials for pregnant women about preventive strategies of perinatal HBV transmission	DH & HA	2020Q4
1.3.2 Integrate education on safe injection and safer sex practices for prevention of HBV and HCV infection with HIV prevention programme	DH	Ongoing
1.3.3 Develop standardised training and education materials on HCV infection for service providers of PWID	DH, HA & NGOs	2022Q1
1.4 Building a supportive environment		
1.4.1 Enhance service capacity of testing and treatment for HBV and HCV infection	DH & HA	Ongoing
1.4.2 Evaluate HBV- and HCV-related service in the public sector to provide useful statistics and support the longer term planning and capacity building	HA	Ongoing



Strategy 2: Surveillance

Action Plan	Action party	Timeline
2.1 Continue surveillance of viral hepatitis and hepatitis B vaccination coverage	DH	Ongoing
2.2 Develop a set of local indicators for monitoring and evaluation of the viral hepatitis elimination strategies for HBV and HCV infection	SCVH	Completed
2.3 Update the HBV and HCV situation according to the results of the Population Health Survey (PHS)	DH	2022Q4
2.4 Adopt a consistent and sustainable approach for the measurement of the Local Indicators for 2015 and 2020	DH & HA	Ongoing



Strategy 3: Prevention

Action Plan	Action party	Timeline
3.1 Reduce mother-to-child transmission of HBV		
3.1.1 Using antivirals to prevent MTCT of HBV		
3.1.1.1 Establish a policy initiative to provide HBsAg-positive mothers with high viral load with a treatment option to use antivirals	SCVH	Completed
3.1.1.2 Refer all HBsAg-positive mothers in HA for care of HBV infection	HA	2021Q1
3.1.1.3 Start using antivirals to prevent MTCT in selected HA hospitals as pilot	HA	2020Q1
3.1.1.4 Start using antivirals to prevent MTCT in all HA birthing hospitals	HA	2020Q3
3.1.1.5 Provide professional training to specialists in O&G, public and private, about the use of antivirals to prevent MTCT	DH & HA	2021Q2
3.1.1.6 Review the acceptance of using antivirals to prevent MTCT	DH & HA	2022Q2
3.1.2 Post-vaccination serologic testing		
3.1.2.1 Establish a policy initiative to provide PVST to babies born to HBsAg-positive mothers	SCVH	Completed
3.1.2.2 Establish the implementation plan and resources implication of PVST	DH & HA	2020Q4
3.1.2.3 Provide professional training about PVST programme to obstetricians and paediatricians	DH & HA	2021Q3
3.1.2.4 Establish the logistics and workflow of PVST	DH & HA	2021Q4
3.1.2.5 Implement PVST programme	DH & HA	2022Q1
3.1.2.6 Review the acceptance of PVST programme	DH & HA	2023Q2

Action Plan	Action party	Timeline
3.2 Prevent healthcare-related transmission of HBV and HCV		
3.2.1 Screen all blood donations in a quality-assured manner	HA	Ongoing
3.2.2 Provide treatment to people contracted HCV through blood / blood product transfusion	HA	Ongoing
3.2.3 Conduct regular infection control training, including Standard Precautions and sharps injury or mucosal contact prevention and management	DH & HA	Ongoing
3.3 Reduce risk and disease burden in vulnerable populations		
3.3.1 Intensify condom programming and take harm reduction approach	DH	Ongoing



Strategy 4: Treatment

Action Plan	Action party	Timeline
4.1 Enhancement of treatment for HBV infection		
4.1.1 Augment diagnosis and treatment capacity for HBV infection, in terms of laboratory, equipment, drug and model of care	HA	Ongoing
4.1.2 Review the service provided by nurse clinics	HA	2022Q4
4.1.3 Engage HA hepatologists to explore strategies to enhance service capacity for HBV infection in both public and private settings	DH & HA	2021Q2
4.1.4 Engage primary care physicians to support management of HBV infection	DH & HA	2021Q4
4.1.5 Develop information resources to facilitate management of HBV infection by primary care physicians	DH & HA	2023Q1
4.1.6 Promulgate the information resources to primary care physicians	DH & HA	2023Q3
4.1.7 Estimate the service need of ultrasound for HCC surveillance	DH & HA	2021Q2
4.2 Expansion of access to direct-acting antivirals for HCV		
4.2.1 Establish a policy initiative to deploy DAA in HCV treatment in a stepwise manner	HA	Completed
4.2.2 Expand DAA treatment for hepatitis C patients with METAVIR fibrosis stages F2 or above	HA	Completed
4.2.3 Expand DAA treatment for all hepatitis C patients	HA	2021Q4
4.2.4 Review the number of patients treated with DAA	HA	2023Q1
4.3 Micro-elimination of HCV infection		
4.3.1 Screen and treat patients with end stage renal failure on dialysis		
4.3.1.1 Establish a policy initiative to provide DAA for HCV treatment in all patients undergoing dialysis	SCVH	Completed
4.3.1.2 Start using DAA to treat HCV infection in all patients undergoing dialysis	HA	2020Q1

Action Plan	Action party	Timeline
4.3.2. Screen and treat patients co-infected with human immunodeficiency virus		
4.3.2.1 Establish a policy initiative to provide DAA for HCV treatment in all HIV-positive patients	SCVH	Completed
4.3.2.2 Start using DAA to treat HCV infection in all patients co-infected with HIV	DH & HA	2020Q4
4.3.2.3 Review the number of patients co-infected with HCV and HIV treated with DAA	DH & HA	2023Q2
4.3.2.4 Assess the number of re-infection among patients co-infected with HCV and HIV after completion of effective HCV treatment	DH & HA	2024Q2
4.4 Promotion of HCV testing in people who inject drugs		
4.4.1 Establish a policy initiative to promote HCV testing in PWID, who are attending methadone clinics (MCs) or under the custody of Correctional Services Department, for treatment	SCVH	Completed
4.4.2 Provide specific educational information about HCV transmission, testing and treatment to PWID	DH	2021Q1
4.4.3 Engage professional staff and other workers serving PWID at MCs by promoting the importance of HCV infection	DH	2021Q2
4.4.4 Identify testing options and algorithms for HCV testing, including the carrying out of a pilot programme, at MCs	DH	2021Q4
4.4.5 Educate and engage staff of Correctional Services Department	DH & CSD	2021Q4